¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood enzyme level"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • blood gas
    Ç÷¾×°¡½º
  • blood gas apparatus
    Ç÷¾×°¡½ººÐ¼®ÀåÄ¡
  • blood gas solubility coefficient
    Ç÷¾×°¡½º¿ëÇØ°è¼ö
  • blood glucose
    Ç÷´ç
  • blood glucose monitoring
    Ç÷´ç°¨½Ã
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çüü°è
  • blood grouping
    Ç÷¾×Çü°Ë»ç
  • blood line
    Ç÷Á·°è, Ç÷Åë
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood mole
    Ç÷¾×±âÅÂ
  • blood plasma
    Ç÷Àå
  • blood pool scan
    Ç÷¾×¿õµ¢À̽ºÄµ, Ç÷¾×Àú·ù½ºÄµ
  • blood pressure
    Ç÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • blood film
    Ç÷¾×µµ¸», Ç÷¾×¹Ù¸¥Ç¥º»
  • blood flow
    Ç÷·ù, ÇÇÈ帧
  • blood fluke
    ÁÖÇ÷ÈíÃæ
  • blood gas
    Ç÷¾×°¡½º, Ç÷¾×±âü
  • blood glucose
    Ç÷´ç
  • blood group
    Ç÷¾×Çü
  • blood grouping
    Ç÷¾×Çü°Ë»ç
  • blood line
    Ç÷Á·°è
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • blood mole
    Ç÷¾×±âÅÂ
  • blood plasma
    Ç÷Àå
  • blood pressure
    Ç÷¾Ð
  • blood product
    Ç÷¾×Á¦Á¦
  • blood recipient
    ¼öÇ÷ÀÚ
  • blood resin
    Ç÷¾×¼öÁö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • enzyme, extracellular
    ±Õü¿ÜÈ¿¼Ò, ¼¼Æ÷¿ÜÈ¿¼Ò
  • enzyme, receptor destroying (RDE)
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • enzyme, restriction
    Á¦ÇÑÈ¿¼Ò
  • enzyme-antibody conjugate
    È¿¼Ò-Ç×ü ¹èÇÕü
  • enzyme-antienzyme reaction
    È¿¼ÒÇ×È¿¼Ò¹ÝÀÀ.
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò¿¬°ü ¸é¿ªÀü±âÀü´ÞÁ¡
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü¸é¿ªÈíÂø¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay (ELISA)
    ¿¤¸®ÀÚ °Ë»ç
  • enzyme-multiplied/mediated immunoassay
    È¿¼Ò´ÙÁß/¸Å°³ ¸é¿ªÃøÁ¤(¹ý)
  • erythrocyte enzyme deficiency
    ÀûÇ÷±¸È¿¼Ò°áÇÌÁõ
  • extracellular enzyme
    ¼¼Æ÷¿ÜÈ¿¼Ò, ü¿ÜÈ¿¼Ò
  • fibrinolytic enzyme
    ¼¶À¯¼Ò¿ëÇØÈ¿¼Ò.
  • flavin enzyme
    Ç÷¹À̺óÈ¿¼Ò.
  • glycine cleavage enzyme system
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • insoluble enzyme
    ºÒ¿ë¼ºÈ¿¼Ò(ÝÕéÁàõý£áÈ)
  • interconvertible enzyme
    »óÈ£Àüȯȿ¼Ò(ßÓû»ï®üµý£áÈ)
  • isodynamic enzyme
    ¾ÆÀ̼ҵ¿Àû(ÔÑîÜ) È¿¼Ò(ý£áÈ)
  • joining enzyme
    Á¢ÇÕÈ¿¼Ò(ïÈùêý£áÈ)
  • key enzyme
    ¿­¼èÈ¿¼Ò(ý£áÈ)
  • late enzyme
    ¸¸±âÈ¿¼Ò(عѢý£áÈ)
  • latent enzyme
    Àẹȿ¼Ò(íÖÜÑý£áÈ)
  • linked enzyme assay procedure
    ¿¬°èÈ¿¼Ò(ææÍ¨ý£áÈ) ¾Æ½êÀÌ ¹æ½Ä(Û°ãÒ)
  • lytic enzyme
    ¿ëÇØÈ¿¼Ò(éÁú°ý£áÈ)
  • malic enzyme
    ¸»»ê(ß«)È¿¼Ò(ý£áÈ)
  • marker enzyme
    Ç¥ÁöÈ¿¼Ò(øöò½ý£áÈ)
  • metal-activated enzyme
    ±Ý¼ÓȰ¼º È¿¼Ò(ÐÝáÕüÀàõý£áÈ)
  • microencapsulated enzyme
    ¹Ì¼¼ÇǸ·È¿¼Ò(Ú°á¬ù«Ø¯ý£áÈ)
  • modification enzyme
    ¼ö½ÄÈ¿¼Ò(áóãÞý£áÈ)
  • multisubstrate enzyme system
    ´Ù±âÁúÈ¿¼Ò(ÒýѨòõý£áÈ) ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
EI Edmonton injector; electrolyte imbalance; electron impact; electron ionization; emotionally impaired...
EIC elastase inhibition capacity; enzyme inhibition complex
ELIA enzyme-linked immunoassay
ELICT enzyme-linked immunocytochemical technique
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
PDL population doubling level
PRL prolactin level
SL sea level
SL sensation level
SEL socio-economic level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone-marrow blood transfusion
    °ñ¼ö ¼öÇ÷
    °æ°ñ°ú Èä°ñÀÇ °ñ¼ö¿¡ Ç÷¾×À» ÁÖÀÔÇÏ´Â ¼öÇ÷ÀÇ º¯¹ý. Ç×»ó ¾²´Â Á¤¸Æ ³» ¼öÇ÷·Î´Â °¨¼ö¼ºÀÌ Áö³ªÄ¡°Ô °­Çϰųª ¸öÀÌ ºñ¸¸ÇÏ¿© Á¤¸ÆÀ» ã±â ¾î·Á¿î ȯÀÚ ¶Ç´Â À¯¾Æ¸¦ ´ë»óÀ¸·Î ÇÒ °æ¿ì ÀÌ ¹æ¹ýÀ¸·Î ¼öÇ÷ÇÒ ¶§°¡ ÀÖ´Ù. ¶Ç ¹éÇ÷º´À̳ª Àç»ýºÒ·®¼º ºóÇ÷ ȯÀÚ¿¡°Ô´Â ÀÌ ¹æ¹ýÀÌ Á¤¸Æ ¼öÇ÷º¸´Ù ¶Ù¾î³­ È¿°ú°¡ ÀÖ´Ù´Â °ßÇØµµ ÀÖ´Ù. ¹æ¹ýÀº °ñ¼ö õÀÚ¸¦ ÇÏ¿© Á¡Àû ÀåÄ¡ ¶Ç´Â ´ëÇü ÁÖ»ç±â·Î äÇ÷ÇÑ Ç÷¾×À» °ñ¼ö ³»¿¡ ÁÖÀÔÇÑ´Ù. ´Ù·® ¼öÇ÷ÀÌ °¡´ÉÇÏÁö¸¸, ±¹ºÎ ÇÇºÎ¿Í °ñ¸·¿¡ ±¹¼Ò¸¶Ã븦 ÇØ¾ß ÇÒ Çʿ䰡 ÀÖ´Ù. ±×¸®°í Á¤¸Æ ¼öÇ÷º¸´Ù ½Ã°£ÀÌ °É¸®°í ¼¼½ÉÇÑ ÁÖÀǰ¡ ÇÊ¿äÇϸç, ȯÀÚ¿¡°Ô °íÅëÀ» Áְųª, ³Ê¹« »¡¸® ÁÖÀÔÇÏ¸é ±¹¼Ò¿¡ ÅëÁõÀ» ÁÖ´Â µîÀÇ °áÁ¡ÀÌ ÀÖ´Ù.
  • circulating blood volume
    ¼øÈ¯ Ç÷¾×·®
  • collection of blood sample
    äÇ÷
  • complete blood count
    ÀüÇ÷ °Ë»ç, ÀüÇ÷±¸ °è»ê
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • dark blood
    £Àº »öÀÇ Ç÷¾×
  • Diego blood type
    µð¿¡°í½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. 1954³â º£³×¼ö¿¤¶óÀÇ µð¿¡°í°¡¿¡¼­ ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ ȯÀÚÀÇ ¾î¸Ó´Ï Ç÷û¿¡¼­ Ç×ü°¡, ¾Æ¹öÁö¿¡°Ô¼­´Â Ç׿øÀÌ ¹ß°ßµÇ¾ú´Ù. Di Ç×ü¿¡ ´ëÇØ ÀûÇ÷±¸°¡ ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀ» Di
  • disorder of blood platelet
    Ç÷¼ÒÆÇ Àå¾Ö
  • Dombrock blood type
    µ¼ºê·Ï½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. »ç¶÷ÀÇ Ç÷±¸ °¡¿îµ¥ Ç×Do Ç×ü¿Í ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Do
  • E-blood group
    ÀÌ½Ä Ç÷¾×Çü
    »ç¶÷ÀÇ Ç÷¾×ÇüÀÇ Çϳª. OÇü ÀÌ¿ÜÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ Áß¿¡¼­ ¹ìÀå¾îÀÇ Ç÷û ¼Ó¿¡ Á¸ÀçÇÏ´Â ÀÀÁý¼Ò¿¡ °­ÇÏ°Ô ¹ÝÀÀÇÏ´Â °ÍÀ» EÇü, ¹ÝÀÀÀÌ ¾àÇÑ °ÍÀ» eÇüÀ¸·Î ÇÏ´Â Ç÷¾×ÇüÀ» ¸»ÇÑ´Ù. EÇüÀº ABO½ÄÀÇ BÇü¿¡ °¡Àå ¸¹°í, A, AB ¼øÀ¸·Î ºóµµ°¡ ³·´Ù. ¶ÇÇÑ À¯ÀüÀÚÇü°úµµ °ü°è°¡ ÀÖÀ¸¸ç II, II
  • effective blood volume
    À¯È¿ Ç÷¾×·®
  • electromagnetic blood flowmeter
    ÀüÀÚ±â Ç÷·ù ÃøÁ¤±â
  • fresh blood
    ½Å¼± Ç÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
enzyme stabilisation Reducing the chances that an enzyme will inactivate in vitro (see enzyme inactivation) by changing the environmental conditions (such as pH, temperature, concentration of salt, etc.) or by attaching organic groups to it or changing some of its amino acid subunits.
(09 Oct 1997)
enzyme stability The extent to which an enzyme retains its structural conformation or its activity when subjected to storage, isolation, and purification or various other physical or chemical manipulations, including proteolytic enzymes and heat.
(12 Dec 1998)
enzyme-substrate complex A noncovalent complex of two molecules; often referring to the enzyme-substrate complex in an enzyme-catalyzed reaction.
Compare: central complex, Michaelis complex.
Synonym: enzyme-substrate complex.
(05 Mar 2000)
extracellular enzyme <enzyme> An enzyme performing its functions outside a cell; e.g., the various digestive enzyme's.
Synonym: exoenzyme, lyoenzyme.
(05 Mar 2000)
yellow enzyme Any enzyme that possesses a flavin nucleotide as coenzyme; e.g., xanthine oxidase, succinate dehydrogenase.
Synonym: yellow enzyme.
(05 Mar 2000)
UDP-N-acetylglucosamine-lysosomal-enzyme-N-acetylglucosaminephosphotransferase <enzyme> Fibroblasts from patients with i-cell (mucolipidosis II) and pseudo-hurler polydystrophy (mucolipidosis III) are deficient in above enzyme; for n-acetylglucosamine transferred to dolichyl phosphate see EC 2.7.8.15
Registry number: EC 2.7.8.17
Synonym: udpgnac gp gnac phosphotransferase, udpgnac phosphotransferase, uridine 5'-diphosphate-n-acetylglucosamine glycoprotein n-acetylglucosaminylphosphotransferase, n-acetylglucosamine-1-phosphotransferase, n-agapt, udp-n-acetylglucosamine-lysosomal glycoprotein n-acetylglucosaminylphosphotransferase, udp-acetylglucosamine-glycoprotein n-acetylglucosamine-1-phosphotransferase
(26 Jun 1999)
UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase <enzyme> An enzyme that participates in the posttranslational modification of a number of lysosomal proteins; a deficiency or defect in this enzyme results in two forms of mucolipidoses, I-cell disease, and pseudo-Hurler polydystrophy.
(05 Mar 2000)
Kornberg enzyme DNA polymerase I from Escherichia coli.
(05 Mar 2000)
1,4-alpha-glucan branching enzyme <enzyme> In glycogen or amylopectin synthesis, the enzyme that catalyses the transfer of a segment of a 1,4-alpha-glucan chain to a primary hydroxy group in a similar glucan chain.
Chemical name: 1,4-alpha-D-Glucan:1,4-alpha-D-glucan 6-alpha-D-(1,4-alpha-D-glucano)-transferase
Registry number: EC 2.4.1.18
(12 Dec 1998)
liver enzyme <biochemistry> Special proteins found in the cells of the liver that are responsible for catalysing specific metabolic reactions. They may become elevated in the bloodstream in conditions of hepatitis or liver cancer.
See: liver function tests.
(27 Sep 1997)
lysosomal enzyme <biochemistry> A range of degradative enzymes, most of which operate best at acid pH. The best known marker enzymes are acid phosphatase and glucuronidase, but many others are known.
(18 Nov 1997)
ABO blood group <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells.
According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom.
Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood.
Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors.
And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction.
(04 Jul 1999)
Almen's test for blood Glacial acetic acid, gum guaiac solution, and hydrogen peroxide are added to an aqueous suspension of the suspected stain; if occult blood or blood pigment is present, a blue colour develops.
Synonym: guaiac test, Schonbein's test, van Deen's test.
(05 Mar 2000)
arterial blood Blood that is oxygenated in the lungs, found in the left chambers of the heart and in the arteries, and relatively bright red.
(05 Mar 2000)
arterial blood gas A test which analyses arterial blood for oxygen, carbon dioxide and bicarbonate content in addition to blood pH. Used to test the effectiveness of respiration.
Acronym: ABG
(17 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á